Heart rate variability and peripheral nerve conduction velocity in relation to blood lead in newly hired lead workers. by Yu, C.G. et al.
1Yu C-G, et al.  Occup Environ Med 2019;0:1–7. doi:10.1136/oemed-2018-105379
Original article
Heart rate variability and peripheral nerve conduction 
velocity in relation to blood lead in newly hired 
lead workers
cai-guo Yu,1,2 Fang-Fei Wei,1 Wen-Yi Yang,1 Zhen-Yu Zhang,3 Blerim Mujaj,1 
lutgarde thijs,1 Ying-Mei Feng,2 Jan a Staessen1,4
Workplace
To cite: Yu c-g, 
Wei F-F, Yang W-Y, et al. 
Occup Environ Med epub 
ahead of print: [please include 
Day Month Year]. doi:10.1136/
oemed-2018-105379
1Department of cardiovascular 
Sciences, University of leuven, 
leuven, Belgium
2Department of endocrinology, 
Beijing lu He Hospital and 
Key laboratory of Diabetes 
Prevention and research, 
capital Medical University, 
Beijing, china
3institut Universitaire de 
Médecine Sociale et Préventive, 
University of lausanne, 
lausanne, Switzerland
4cardiovascular research 
institute Maastricht, Maastricht 
University, Maastricht, the 
netherlands
Correspondence to
Dr Jan a Staessen, Department 
of cardiovascular Diseases, 
University of leuven, leuven 
3000, Belgium;  
 jan. staessen@ med. kuleuven. be
received 25 July 2018
revised 9 January 2019
accepted 22 January 2019
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY. 
Published by BMJ.
AbsTrACT
Objectives Previous studies relating nervous activity 
to blood lead (Bl) levels have limited relevance, because 
over time environmental and occupational exposure 
substantially dropped. We investigated the association of 
heart rate variability (HrV) and median nerve conduction 
velocity (ncV) with Bl using the baseline measurements 
collected in the Study for Promotion of Health in 
recycling lead (nct02243904).
Methods in 328 newly hired men (mean age 28.3 
years; participation rate 82.7%), we derived HrV 
measures (power expressed in normalised units (nu) 
in the high-frequency (HF) and low-frequency (lF) 
domains, and lF/HF) prior to long-term occupational lead 
exposure. Five-minute ecg recordings, obtained in the 
supine and standing positions, were analysed by Fourier 
transform or autoregressive modelling, using cardiax 
software. Motor ncV was measured at the median 
nerve by a handheld device (Brevio nerve conduction 
Monitoring System, neuMed, West trenton, nJ, USa). 
Bl was determined by inductively coupled plasma mass 
spectrometry.
results Mean Bl was 4.54 µg/dl (iQr 2.60–8.90 µg/
dl). Mean supine and standing values of lF, HF and lF/
HF were 50.5 and 21.1 nu and 2.63, and 59.7 and 10.9 
nu and 6.31, respectively. Orthostatic stress decreased 
HF and increased lF (p<0.001). ncV averaged 3.74 
m/s. analyses across thirds of the Bl distribution and 
multivariable-adjusted regression analyses failed to 
demonstrate any association of HrV or ncV with Bl.
Conclusions at the exposure levels observed in our 
study, autonomous nervous activity and ncV were not 
associated with Bl.
Trial registration number nct02243904
bACkgrOund
Almost two decades ago, Araki and coworkers 
reviewed 102 articles on the effects of lead expo-
sure on the peripheral, central and autonomous 
nervous system in workers.1 They reported that 
the reduction in the peripheral nerve conduction 
velocity , together with effects on postural balance 
and ECG heart rate variability , occurs at a mean 
blood lead concentration of 30 – 40  µg/dL. 1 A 
major limitation of the previous studies is that they 
have limited relevance in view of the current envi-
ronmental exposure to lead. Indeed, in the USA , the 
National Health and Nutrition Examination Survey 
(NHANES) documented a progressive decline in 
the geometric blood lead concentration over time. 
Among adults, mean blood lead Among adults, 
mean blood levels decreased from 13.1  µg/dL in 
NHANES II (1976 – 1980)2 3 to 1.2 – 2.76  µg/dL in 
NHANES III (1988 – 1994),2 3 and to 1.64  µg/dL 
in NHANES IV (1999 – 2002) and in later exam-
ination cycles.4 5 Furthermore, a PubMed search 
without limitation of language or publication date 
key messages
What is already known about this subject?
 ► Previous studies relating nervous system 
activity to lead exposure have limited relevance 
because of substantially lower current 
environmental and occupational exposure.
 ► At high exposure levels in an occupational 
context, lead is neurotoxic, leading to cardiac 
autonomic dysfunction and reduced peripheral 
nerve conduction velocity.
What are the new findings?
 ► In 328 newly hired workers prior to chronic 
occupational lead exposure, the geometric 
mean blood lead concentration was 4.54 μg/dL 
(IQR 2.60–8.90).
 ► At these exposure levels, there was no 
association of heart rate variability with blood 
lead.
 ► These results were consistent irrespective of 
body position or the way heart rate variability 
was analysed in the frequency domain.
 ► There was no association between motor nerve 
conduction velocity assessed at the median 
nerve and blood lead.
How might this impact on policy or clinical 
practice in the foreseeable future?
 ► At current environmental and occupational 
exposure levels in the USA, lead may not be 
a cause of central autonomous or peripheral 
nervous dysfunction.
 ► As occupational safety and health regulatory 
agencies in North America, Europe and 
Australasia are proposing more stringent 
workplace limits for lead, this study may 
provide valuable information on blood lead 
levels that may not cause adverse health effects 
associated with occupational lead exposure.
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and using as search terms ‘ lead exposure’ in association with ‘ 
heart rate variability ’ or ‘ sympathetic activity’ or ‘ parasym-
pathetic activity’ or ‘ nerve conduction velocity ’ revealed that 
few relevant articles were published since 2000,6–15 and most 
publications focused on potential neurotoxic mechanisms in an 
experimental setting.10–15 Against this background, our aim was 
to investigate the association of heart rate variability and periph-
eral nerve conduction velocity with blood lead at low exposure 
levels, using the baseline measurements collected in the ongoing 
Study for Promotion of Health in Recycling Lead (SPHERL; 
NCT02243904) in newly hired workers prior to occupational 
lead exposure.16 
METHOds
study participants
SPHERL complies with the Helsinki declaration for investiga-
tions in humans. SPHERL is a longitudinal study of newly hired 
lead workers at battery manufacturing and lead recycling plants 
in the USA.16 From 1 May 2015 until 19 September 2017, a total 
of 556 men applied for a job and underwent a pre-employment 
physical examination, at which whole blood lead was measured 
as part of the routine health check-up put in place prior to 
employment. These pre-employment data are not part of the 
SPHERL study. Of 556 men who underwent this pre-employ-
ment assessment, all were invited to participate in SPHERL; 460 
provided written informed consent and underwent the SPHERL 
baseline examination (participation rate, 82.7%). Of those, 
424 had their ECG recorded and peripheral nerve conduction 
velocity and blood lead measured. We excluded 96 workers 
from the current analysis of the SPHERL baseline data, because 
of previous occupational exposure to lead (n=41), because the 
ECG was of insufficient quality (n=40), or because continuously 
distributed variables were more than 3 SDs above the mean in 
the whole study population (n=15). However, no worker was 
excluded because of a high blood lead concentration. Thus, the 
number of workers statistically analysed totalled 328.
Clinical measurements
Blood pressure was the average of five consecutive auscultatory 
readings obtained with a standard mercury sphygmomanometer 
after the workers had rested for 5 min or longer in the sitting 
position.16 Mean arterial pressure was diastolic pressure plus 
one-third of the difference between systolic and diastolic pres-
sure. High blood pressure was a level of ≥140 mm Hg systolic, 
or ≥90 mm Hg diastolic, or use of antihypertensive drugs. Body 
mass index was body weight (kg) divided by height squared (m2). 
The umbilicus and greater trochanter were the landmarks for 
measuring waist and hip circumference. Study nurses adminis-
tered validated questionnaires, inquiring about each worker’s 
medical history, occupations, exposure to heavy metals, smoking 
and drinking habits, intake of medications and lifestyle.
biochemical measurements
Venous blood samples were obtained after 8–12 hours of fasting. 
Blood lead levels were determined on whole blood by induc-
tively coupled plasma mass spectrometry at an analytical labo-
ratory certified for blood lead analysis in compliance with the 
provisions of the OSHA Lead Standard, 29CFR 1910.1025 
(Occupational Safety and Health Administration ( www. osha. 
gov)). Prior to analysis, the specimens were digested with nitric 
acid and spiked with an iridium internal standard. The detec-
tion limit was 0.5 µg/dL. Serum total and high-density lipopro-
tein (HDL) cholesterol and blood glucose were measured by 
automated enzymatic methods and serum insulin by ELISA. The 
online supplementary material provides detailed information on 
the accuracy and the repeatability of the blood lead measure-
ments as well as on the performance of the laboratory in profi-
ciency testing for lead and the other biochemical analytes.
Heart rate variability
At enrolment, the study nurses record a standard 12-lead ECG 
by means of the paperless Cardiax device. Heart rate vari-
ability was measured from 5 min ECG recordings in supine and 
standing positions, using the Cardiax software, V.4.14.0 (Inter-
national Medical Equipment Developing, Budapest, Hungary). 
The Cardiax software allows exporting all ECG measurements 
into an Excel workbook, which was subsequently imported into 
SAS V.9.4, using standardised programming statements, thereby 
excluding any observer-induced bias. The software computes 
the power spectrum in the frequency domain by fast Fourier 
transform and by autoregressive modelling (online supplemen-
tary material) and provides the low-frequency (0.04–0.15 Hz) 
and high-frequency (0.15–0.40 Hz) components of heart rate 
variability in milliseconds and the low to high frequency ratio. 
Normalised units of low and high-frequency power were calcu-
lated as the low and high-frequency power divided by the differ-
ence (total power − very-low-frequency power) ×100. Heart 
rate variability reflects the activity of the autonomous nervous 
system. Efferent vagal activity is a major contributor to high-fre-
quency power. The interpretation of low-frequency power is 
more controversial and reflects sympathetic modulation or both 
sympathetic and parasympathetic activity. Total frequency power 
decreases during sympathetic activation, whereas the reverse 
occurs during vagal activation.17
Peripheral nerve conduction velocity
The study nurses used a handheld device and accompanying soft-
ware (Brevio Nerve Conduction Monitoring System, NeuMed, 
West Trenton, NJ, USA) to stimulate the median nerve at a grad-
ually increasing voltage until the maximum compound motor 
action potential of the short thumb abductor muscle was reached. 
Nerve conduction velocity was measured in the workers’ right 
and left hands. To check the quality of the nerve conduction 
velocity, we randomly selected 40 workers and produced the 
Bland and Altman statistics,18 comparing the velocity at the left 
and right arms (see online supplementary figure S1). The bias 
(right minus left side) was 0.014 m/s (p=0.83). The repeatability 
coefficient was 0.82.
data analyses
Database management and statistical analyses were done using 
SAS V.9.4 software (Cary, NC, USA). The flow and quality 
control of the data are described in the published protocol.16 
Departure from normality was evaluated using Shapiro-Wilk 
statistic. Skewness and kurtosis were computed as the third 
and fourth moments of the mean divided by the cube of the 
SD. We applied a logarithmic transformation to normalise the 
distributions of total power, the low to high frequency ratio in 
the supine and standing positions, the orthostatic changes in all 
heart rate variability measurements and blood lead and serum 
insulin. The central tendency (spread) of normally distributed 
variables was represented by the arithmetic (SD) or geometric 
(IQR) mean. To compare means and proportions, we applied 
a t-statistic or analysis of variance, as appropriate, and the χ2 
(with right symbol and format in the on-line system) statistic or 
Fisher’s exact test, respectively.
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In exploratory analyses, we assessed heart rate variability and 
nerve conduction velocity across thirds of the blood lead distri-
bution or by using unadjusted linear regression. P values for 
trend were computed by the χ2(with right symbol and format 
in the online system) statistic for categorical variables or by 
regressing continuously distributed variables on a design vari-
able identifying the thirds of the blood lead distribution with 
as values 1, 2 or 3. We used stepwise regression analysis with 
the p value for covariables to enter and stay in the models set 
at 0.15. The covariables considered were age, body mass index, 
waist to hip ratio, mean arterial pressure, heart rate, current 
smoking and drinking, history of diabetes and kidney disease, 
treatment of hypertension, serum insulin levels (logarithmically 
transformed) and the total to HDL cholesterol ratio. Signifi-
cance was a two-tailed α-level of 0.05 or less.
rEsulTs
Characteristics of participants
Table 1 lists the characteristics of the participants in all workers 
combined and after stratification by thirds of the blood lead 
distribution. The 328 newly hired workers included 149 Whites 
(45.4%), 155 Hispanics (47.3%), 12 Blacks (3.7%), 3 Asians 
(0.9%) and 9 workers of mixed ethnic descent (2.7%). Among 
132 workers reporting current alcohol intake drinkers (40.2%), 
the median alcohol consumption was 4.8 g/day (IQR 1.8–9.3 g/
day); 66 workers (50%) reported an alcohol consumption of 5 g/
day or more.
At the pre-employment physical examination, the geometric 
mean blood lead concentration was 2.47 µg/dL (IQR 2.00–3.00 µg/
dL). Of the 328 workers, 286 (87.2%) were involved in the 
manufacturing process and were therefore exposed, whereas 42 
(12.8%) employees had clerical or warehouse tasks or were sales 
representatives without lead exposure. The geometric mean lead 
concentration in inhaled air in the lead-exposed workers according 
to National Institute for Occupational Safety and Health standards 
(NIOSH; https://www. cdc. gov/ niosh/ topics/ lead/ limits. html) was 
11.3 µg/m3 (IQR 6.0–21.0 µg/m3). Lead in the air was not moni-
tored in departments of the plants, where there was no lead expo-
sure. The first assessment of blood lead for the current study, done 
simultaneously with the heart rate variability and peripheral nerve 
conduction velocity measurements, was performed 21 days (IQR 
10–31 days) after workers had started employment. At this time 
point, the geometric mean blood lead concentration was 4.54 µg/
dL (IQR 2.50–8.30 µg/dL; figure 1). Across the lead categories, the 
prevalence of high blood pressure, body mass index, the waist to 
hip ratio, total cholesterol and the total to HDL cholesterol ratio 
all decreased (p≤0.045; table 1).
Heart rate variability
Table 2 provides the heart rate variability measurements derived 
by Fourier transform in all workers and after stratification by 
thirds of the blood lead distribution. The corresponding measure-
ments derived by autoregressive modelling appear in online 
supplementary table S1. Analyses across thirds of the blood lead 
distribution did not reveal any significant trend in heart rate or 
in the measures of heart rate variability as derived by Fourier 
transform (table 2) or by autoregressive modelling (see online 
supplementary table S1). These findings were consistent for 
observations made in the supine and standing positions as well as 
for the orthostatic changes in heart rate and heart rate variability.
Peripheral nerve conduction velocity
The peripheral nerve conduction velocity averaged 3.74 (0.53) 
m/s for the left hand and 3.77 (0.70) m/s for the right hand. 
Table 1 Characteristics of the workers
Characteristic All workers
stratified by thirds of the blood lead distribution
<3.1 µg/dl 3.1–7.0 µg/dl >7.0 µg/dl P value
Number in category 328 106 112 110
Number (%) with characteristic
  Current smoking 96 (29.3) 25 (23.6) 38 (33.9) 33 (30) 0.24
  Current alcohol intake 132 (40.2) 38 (35.9) 52 (46.4) 42 (38.2) 0.24
  High blood pressure 34 (10.4) 9 (8.5) 18 (16.0) 7 (6.4)* 0.045
  Treated hypertension 21 (6.4) 7 (6.6) 11 (9.8) 3 (2.7)* 0.10
  Diabetes mellitus 7 (2.1) 2 (1.9) 3 (2.7) 2 (1.8) 0.89
  History of CV disease 17 (5.2) 8 (7.5) 5 (4.5) 4 (3.6) 0.40
Mean of characteristic
  Age (years) 28.3±10.2 28.7±10.1 29.8±11.5 26.4±8.7* 0.090
  Body mass index (kg/m2) 28.6±6.2 29.3±6.5 29.1±6.3 27.5±5.6 0.027
  Waist to hip ratio 0.97±0.07 0.97±0.07 0.98±0.07 0.95±0.07* 0.032
  Systolic pressure (mm Hg) 120.6±9.7 120.5±9.2 122.2±10.0 119.1±9.5* 0.27
  Diastolic pressure (mm Hg) 80.7±7.9 80.2±8.2 81.7±8.0 80.2±7.5 0.95
  Mean arterial pressure (mm Hg) 94.0±7.7 93.7±7.9 95.2±7.8 93.1±7.4 0.62
  Total cholesterol (mg/dL) 169.4±36.9 172.3±37.0 174.0±39.2 162.1±33.6* 0.039
  HDL cholesterol (mg/dL) 45.9±10.5 44.3±9.6 46.5±10.0 47.0±11.7 0.058
  Total to HDL cholesterol ratio 3.88±1.21 4.08±1.29 3.90±1.15 3.66±1.16 0.011
  Insulin (μIU/mL) 7.3 (3.9–12.7) 7.5 (4.5–13.0) 7.4 (4.0–13.0) 6.8 (3.4–11.8) 0.37
  Blood lead (μg/dL) 4.54 (2.50–8.30) 1.81 (1.30–2.60) 4.60 (3.70–5.40)*** 11.0 (8.90–12.2)*** <0.0001
Average values are arithmetic (±SD) or geometric means (IQR). High blood pressure was a level of ≥140 mm Hg systolic, or ≥90 mm Hg diastolic, or use of antihypertensive 
drugs. Mean arterial pressure was diastolic pressure plus one-third of the difference between systolic and diastolic pressure. P values are for linear trend across thirds of the 
blood lead distribution.
Significance of the difference with the adjacent left column: *P≤0.05; ***P≤0.001. 
CV, cardiovascular; HDL, high-density lipoprotein.
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Because there was no difference between both sides (p=0.064), 
in further analyses, we used the mean of both sides, which in 
all workers averaged 3.74 (0.56). Nerve conduction velocity 
also did not show any trend across the thirds of the blood lead 
distribution, averaging 3.78±0.64 m/s, 3.75±0.53 m/s and 
3.70±0.49 m/s in the low, medium and high category of blood 
lead (p value for trend, 0.29).
Correlations with blood lead
Consistent with the categorical analysis and irrespective of body 
position, none of the unadjusted correlations of blood lead with 
heart rate, with the heart rate variability derived by Fourier 
transform (table 3) or autoregressive modelling (see online 
supplementary table S2), or orthostatic changes therein reached 
statistical significance. Figure 2 depicts the correlations for low 
and high-frequency power. Nerve conduction velocity was also 
not correlated with blood lead. The difference associated with a 
10-fold increase in blood lead was −0.09 m/s (95% CI, −0.26 
to 0.08; p=0.29).
Of the covariables considered (see the Methods section), only 
age, heart rate, mean arterial pressure and serum insulin were 
identified as covariables of the heart rate variability indices; for 
nerve conduction velocity, the selected covariables were age, 
waist to hip ratio, mean arterial pressure and the total to high 
cholesterol ratio. With adjustment for covariables, none of the 
correlations of blood lead with heart rate variability, derived 
by Fourier transform (table 3) or autoregressive modelling (see 
online supplementary table S2), or with the orthostatic changes 
therein reached statistical significance. In the multivariable-ad-
justed analysis, nerve conduction velocity was also not correlated 
with blood lead. The point estimate associated with a 10-fold 
increment in blood lead was −0.06 m/s (95% CI, −0.22 to 0.11; 
p=0.51).
disCussiOn
In the newly hired workers enrolled in our current study, the 
geometric mean blood lead concentration was 4.54 µg/dL. The 
key findings were that we failed to demonstrate any associa-
tion of blood lead with the activity of the autonomous nervous 
system, as captured by heart rate variability, or with peripheral 
motor nerve conduction velocity at the level of the median nerve.
Among 413 older men (mean age 72.9 years), enrolled in the 
Veterans Administration Normative Aging Study, patella lead 
averaged 16.3 µg/g.7 With adjustments applied for age, body 
mass index, fasting glucose, serum lipids, smoking and drinking, 
Figure 1 Distribution of logarithmically transformed blood lead. S, K and 
M indicate the coefficients of skewness and kurtosis and the geometric 
mean, respectively. the solid and dotted lines represent the normal and 
kernel density distributions. the p value is for departure of the actually 
observed distribution from normality according to Shapiro-Wilk statistic.
Table 2 Heart rate variability by Fourier transform
Characteristic All workers
stratified by thirds of the blood lead distribution
<3.1 µg/dl 3.1–7.0 µg/dl >7.0 µg/dl P value
Number in category 328 106 112 110
Supine position
  Heart rate (beats/minute) 65.4±10.8 66.9±11.3 65.2±10.2 64.3±10.6 0.080
  Total power (m/s2) 1621 (791 to 3088) 1492 (789 to 2698) 1547 (745 to 3038) 1828 (891 to 3306) 0.14
  Low-frequency power (nu) 50.5±15.6 52.6±15.9 49.0±14.7 50.0±16.1 0.22
  High-frequency power (nu) 21.1±11.8 20.7±11.6 22.4±12.6 20.1±11.0 0.72
  Low to high frequency ratio 2.63 (1.66 to 4.07) 2.80 (1.68 to 4.61) 2.50 (1.56 to 3.67) 2.69 (1.87 to 4.09) 0.67
Standing position
  Heart rate (beats/minute) 77.8±12.7 79.4±13.5 78.0±12.5 76.3±12.0 0.069
  Total power (m/s2) 1445 (818 to 2658) 1458 (745 to 3038) 1258 (840 to 2166) 1624 (891 to 3234)** 0.40
  Low-frequency power (nu) 59.7±16.7 60.5±16.2 58.2±17.7 60.41±16.10 0.99
  High-frequency power (nu) 10.9±7.0 11.7±7.6 10.6±6.7 10.55±6.63 0.23
  Low to high frequency ratio (log) 6.31 (4.19 to 9.64) 5.83 (1.56 to 3.67) 6.34 (4.07 to 9.83) 6.57 (4.49 to 10.3) 0.19
Orthostatic changes
  Heart rate (beats per minute) 12.4 (11.5 to 13.3) 12.5 (10.9 to 14.1) 12.7 (11.2 to 14.2) 12.0 (10.5 to 13.5) 0.62
  Total power (m/s2) 0.89 (0.81 to 0.98) 0.98 (0.82 to 1.17) 0.81 (0.68 to 0.97) 0.89 (0.77 to 1.03) 0.43
  Low-frequency power (nu) 1.19 (1.14 to 1.24) 1.16 (1.07 to 1.25) 1.18 (1.08 to 1.29) 1.23 (1.13 to 1.33) 0.32
  High-frequency power (nu) 0.51 (0.47 to 0.55) 0.56 (0.48 to 0.64) 0.46 (0.40 to 0.53)* 0.50 (0.44 to 0.56) 0.30
  Low to high frequency ratio 2.34 (2.16 to 2.56) 2.08 (1.76 to 2.46) 2.53 (2.19 to 2.88)* 2.44 (2.14 to 2.80) 0.13
Values in the supine and standing positions are arithmetic mean (±SD) or geometric mean (IQR). Orthostatic changes in heart rate are reported as the arithmetic mean of the 
standing minus supine value (95% CI). Orthostatic changes in heart rate variability were computed as the logarithmically transformed standing to supine ratio, for which the 
geometric mean (95% CI) is given. P values are for linear trend across thirds of the blood lead distribution.
Significance of the difference with the adjacent left column: *P≤0.05; **P≤0.01.
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antihypertensive drug treatment, room temperature and season, 
the normalised low and high-frequency power and their ratio 
were not associated with tibia or patella lead. However, there 
was a graded, statistically significant reduction in high-frequency 
power and an increase in low-frequency power and in the low 
to high frequency ratio in association with higher patella lead 
as the number of metabolic abnormalities increased from none 
to 3 or more. The study included 20% of patients with diabetes 
mellitus, 70% with hypertension and approximately 30% with 
a history of cardiovascular disease, so this study of older men 
cannot be extrapolated to the general population. Moreover, the 
participants were recruited in 1963 and examined from 1991 
until 2002,7 when according to NHANES data, blood lead levels 
in the general population in the USA averaged from 2.76 µg/dL 
(1988–1994)3 to 1.64 µg/dL (1999–2002).4 Lead is a cumulative 
toxin and bone lead reflects lifetime rather than recent expo-
sure. The same authors reported 2 years later that the association 
between heart rate variability and bone lead might be modulated 
by air pollutants, such as ozone and sulfate, with higher exposure 
to the air pollutants making study participants more susceptible 
to cardiac autonomic dysfunction in response to lead exposure.19
A cross-sectional study of labourers working in the copper 
industry in Germany involved 109 clinically healthy exposed 
male workers (mean age 42.6 years) and 27 non-exposed 
matched controls, who both underwent psychometric strain 
testing.6 In exposed workers, the blood lead concentration aver-
aged 31.2 µg/dL. Exposed compared with non-exposed partic-
ipants had a lower heart rate, higher sinus arrhythmia and a 
dysregulated heart rate variability at rest, during psychometric 
strain testing and after recovery.6 The authors’ interpretation was 
that long-term lead exposure (19 years) was associated with inhi-
bition of vagal activity,6 supporting the authors’ hypothesis that 
the long vagal nerve, compared with shorter sympathetic fibres, 
is more vulnerable to the neurotoxic effects of lead. A 4-year 
follow-up study of 17 exposed workers, during which blood lead 
increased from 39.4 to 43.3 µg/dL6 and a later study with focus 
on neurocognitive performance6 produced confirmatory results. 
The latter study involved 70 exposed workers whose blood lead 
at examination averaged 30.4 μg/dL.6 However, an earlier study 
of 98 lead-exposed workers, whose blood lead ranged from 40 
to 75 mgμg/dL and who were compared with 85 controls, failed 
to detect any influence on the autonomic nervous system, as 
assessed by quantifying sinus arrhythmia.20
A meta-analysis of summary statistics, derived from 49 studies 
for the association between nerve conduction velocity and blood 
lead, included 1629 controls (women 21.0%) and 2825 exposed 
individuals (12.9%).21 Age and blood lead averaged 39.2 years 
and 15.7 µg/dL in controls, and 38.4 years and 53.0 µg/dL in 
exposed individuals.21 In exposed individuals compared with 
controls, conduction velocity was reduced in the median, ulnar 
and radial nerves in the arm, and in the deep peroneal nerve 
in the leg. Distal latencies of the median, ulnar and deep pero-
neal nerves were longer.20 No changes in the amplitudes of 
compound muscle or nerve action potentials were detected. The 
Table 3 Correlations of blood lead with heart rate variability measured by Fourier transform
Variable
unadjusted Adjusted
Estimate (95% Ci) P value Estimate (95% Ci) P value
Supine position
  Total power (%) 23.3 (–9.6 to 68.7) 0.19 3.0 (–20.4 to 33.0) 0.82
  Low-frequency power (nu) –3.00 (–7.83 to 1.83) 0.22 –2.26 (–7.09 to 2.57) 0.36
  High-frequency power (nu) –1.59 (–5.24 to 2.06) 0.39 –2.60 (–6.01 to 0.81) 0.13
  Low to high frequency ratio (%) –1.8 (–20.8 to 21.6) 0.87 6.2(–12.9 to 29.1) 0.56
Standing position
  Total power (%) 11.7 (–17.0 to 50.3) 0.46 –6.0 (–26.2 to 19.7) 0.61
  Low-frequency power (nu) –1.037 (–6.22 to 4.14) 0.69 –1.36 (–6.48 to 3.76) 0.60
  High-frequency power (nu) –1.61 (–3.78 to 0.55) 0.14 –1.66 (–3.79 to 0.47) 0.13
  Low to high frequency ratio (%) 14.0 (–7.3 to 40.3) 0.21 –14.0 (–4.9 to 42.2) 0.14
Orthostatic change
  Total power (%) –8.8 (–31.8 to 17.5) 0.47 –8.8 (–31.8 to 17.5) 0.47
  Low-frequency power (%) 4.7 (–6.7 to 20.2) 0.42 –2.3 (–8.8 to 17.4) 0.74
  High-frequency power (%) –8.8 (–27.6 to 14.8) 0.40 –6.7 (–24.2 to 14.8) 0.61
  Low to high frequency ratio (%) 14.8 (–8.8 to 47.9) 0.22 7.2 (–14.9 to 34.9) 0.52
Covariables in adjusted models included age, heart rate (or heart rate change for orthostatic changes), mean arterial pressure and serum insulin. Association sizes, given with 
95% CI, are the difference in the outcome variable associated with a 10-fold increase in the blood lead concentration. For logarithmically transformed outcomes, differences are 
given as a percentage or as a percentage change on assuming the standing from the supine position.
Figure 2 correlations of blood lead with low-frequency (a–c) and high-
frequency (D–F) power in the supine (a, D) and standing (B, e) positions 
and with the orthostatic changes therein (c, F). For each association the 
unadjusted regression line with 95% ci is depicted. adjustment for relevant 
covariables, identified by stepwise regression, including age, heart rate (or 
orthostatic change in heart rate), mean arterial pressure and serum insulin 
did not materially alter these relationships. HFP, high-frequency power; lFP, 
low-frequency power; nu, normalised unit. 
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lowest concentration, at which a relation with blood lead was 
detected, was 33.0 µg/dL for the nerve conduction velocity of 
the median sensory nerve.21
An association between nerve conduction velocity and 
blood lead might reflect either a direct neurotoxic effect or 
an indirect effect mediated by lead-induced dysfunction of 
other organs, such as the kidney.21 In addition, genetic vari-
ation (rs1800435) in the δ-aminolevulinic acid dehydratase 
(ALAD) might modify the neurotoxic effects of lead.21 Indeed, 
the second enzyme in the haem biosynthetic pathway, ALAD 
is a homo-octameric protein encoded by a gene localised on 
human chromosome 9q34.9 Expression of the two common 
alleles, ALAD1 and ALAD2, results in a polymorphic enzyme 
system with three distinct isozymes.9 Individuals heterozygous 
or homozygous for the ALAD2 allele have significantly higher 
blood lead levels than do ALAD1 homozygotes, when exposed 
to low or high levels of lead in the environment.22 In line with 
the literature,22 among 461 Chinese lead-exposed workers, 
matched with 175 unexposed controls,9 the lead-exposed 
workers had a higher fraction of the ALAD1-2/2-2 genotype 
than unexposed controls (7.8% vs 2.3%, p=0.01). The lead 
levels in blood and urine were higher in exposed workers 
carrying the ALAD2 allele compared with ALAD1 homozy-
gotes (median blood lead 60.6 vs 49.9 μg/dL; 233 vs 164 μg/g 
creatinine), while there was no significant difference in the 
unexposed controls (2.4 vs 3.7 μg/dL and 3.9 vs 6.4 μ g/g 
creatinine, respectively). High blood and urinary lead were 
associated with lower sensory and motor conduction veloci-
ties in the median, ulnar and peroneal nerves.9 This Chinese 
study suggested that ALAD genotypes might modify the 
changes in peripheral nervous conduction velocity in response 
to lead exposure.9
A detailed description of the potential mechanism of neuro-
toxicity is beyond the scope of this study. Experimental studies 
in animals suggested as potential mechanisms: stimulation of 
the sympathetic preganglionic neurons,10 harm to the β-adren-
ergic system in the brain,11 downregulation of cardiac β1-adre-
noceptor activity,14 upregulated expression of P2X4 receptor in 
satellite glial cells of the stellate ganglion,15 increased sensitivity 
of chemoreceptor reflex12 or decreased sensitivity of the baro-
reflex.13 To what extent these animal experiments can be trans-
lated to the human condition remains unclear.
The strong points of our study are that our literature search 
did not reveal other studies that evaluated the association of 
autonomous nervous activity or peripheral nerve conduction 
velocity with blood lead at current exposure levels in humans. 
Our sample size was of the same order of magnitude as in most 
previous studies on heart rate variability or peripheral nerve 
conduction velocity.12 Moreover, confounding by drug treatment 
or previous cardiovascular disease was not an issue in our study. 
Indeed, only 6.1% of the workers were on antihypertensive drug 
treatment and only 5.2% had a history of cardiovascular disease 
(table 1). Nevertheless, our current findings must be interpreted 
within the context of their limitations. First, findings in workers 
cannot be extrapolated to the general population, because of the 
so-called healthy worker effect.23 Second, although our study 
population was ethnically diverse, it included few Asians and 
no women. Finally, a potential limitation of our study was that 
we did not measure bone lead as an exposure marker. Approx-
imately 95% of the total body burden of lead is present in the 
skeleton, and measurement of bone lead levels can provide a 
more accurate measure of the internal dose.24 However, blood 
lead reflects both recent exogenous exposure and endogenous 
redistribution of the lead stored in bone.22
COnClusiOn
In this cross-sectional study, low-level exposure to lead was 
not associated with changes in autonomous nervous activity, as 
exemplified by heart rate variability, or with alterations in periph-
eral nerve conduction velocity. Occupational safety and health 
regulatory agencies in North America, Europe and Australasia 
are proposing more stringent workplace limits for lead, but a 
national expert panel in the USA spent over 2 years discussing 
whether the current OSHA standards for occupational lead 
exposure should be tightened without reaching agreement.25 
SPHERL may provide valuable information on blood lead levels 
that may not cause adverse health effects associated with occupa-
tional lead exposure. The 2-year longitudinal follow-up period 
built into the study design of SPHERL,16 in which blood lead 
levels are expected to increase from environmental to occupa-
tional levels, that is, 20–30 µg/dL, will further inform current 
and pending workplace limits for lead, many of which are in this 
blood lead range. This study design will also attempt to resolve 
the apparent contradiction between general population studies 
showing associations between adverse health effects with blood 
lead levels below 10 µg/dL26 and studies conducted in occupa-
tional cohorts, in whom adverse effects of lead exposure occur 
at much higher blood lead levels.23
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